Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
96 Results for "
LRRK2
" in MedChemExpress (MCE) Product Catalog:
Products (96)
96 Results for "LRRK2" in MCE Product Catalog:
Cat. No.: HY-161571
CAS No.: 3032733-17-5
Target:
Research Areas:
LRRK2-IN-13 (Compound 13) is an inhibitor of LRRK2 (IC50=0.57 nM). LRRK2-IN-13 has brain penetrating properties .
Cat. No.: HY-175651
CAS No.: 2763594-19-8
Target:
Research Areas:
LRRK2-IN-20 (EX. 4.64) is a LRRK2 inhibitor with a pIC50 of 0.7921 nM. LRRK2-IN-20 can be used in Parkinson's disease (PD) research .
Cat. No.: HY-152107A
CAS No.: 2307277-92-3
Target:
Research Areas:
(R,R)-LRRK2-IN-7 is the isomer of LRRK2-IN-7 (HY-152107). LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes.
Cat. No.: HY-145317
CAS No.: 2641059-19-8
Target:
Research Areas:
LRRK2-IN-2 (compoubd 22) is a potent, selective, orally active and brain-penetrant inhibitor LRRK2, with IC50 of <0.6 nM. LRRK2-IN-2 can be used for the research of Parkinson's disease .
Cat. No.: HY-145318
CAS No.: 2641054-60-4
Target:
Research Areas:
LRRK2-IN-3 (compoubd 24) is a potent, selective, orally active and brain-penetrant inhibitor LRRK2, with IC50 of 2.6 nM in human PBMCs. LRRK2-IN-3 can be used for the research of Parkinson's disease .
Cat. No.: HY-144074
CAS No.: 2641054-59-1
Target:
Research Areas:
LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC50 of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .
Cat. No.: HY-153103
CAS No.: 2629192-96-5
Research Areas:
LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), TYK2 and NUAK1, with IC50 values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research .
Cat. No.: HY-177016
CAS No.: 2839667-09-1
Research Areas:
LRRK2-IN-19 is a PROTAC target protein ligand that can be used to synthesize PROTAC JH-XII-03-02 (HY-155150). JH-XII-03-02 is a highly potent and selective LRRK2 PROTAC degrader, which can be used in Parkinson's disease research .
Cat. No.: HY-148353
CAS No.: 1527474-15-2
Target:
Research Areas:
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC50 value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) [2].
Cat. No.: HY-186110
CAS No.: 2839665-11-9
Research Areas:
PROTAC LRRK2 Degrader-5 Formula (V) is a LRRK2 PROTAC degrader. PROTAC LRRK2 Degrader-5 can be used for thet study of the diseases associated with LRRK2, such as Parkinson’s Disease (PD) .
Cat. No.: HY-171802
CAS No.: 3080678-93-6
Research Areas:
PROTAC LRRK2 Degrader-2 is a PROTAC-based degrader targeting LRRK2 with a DC50 of 0.14 nM. PROTAC LRRK2 Degrader-2 recruits LRRK2 or its mutants to the cereblon E3 ubiquitin ligase, thereby mediating the targeted ubiquitination and subsequent proteasomal degradation of LRRK2. PROTAC LRRK2 Degrader-2 can be used in research related to Parkinson's disease .
Cat. No.: HY-111493R
CAS No.: 1802525-61-6
Target:
Research Areas:
LRRK2 inhibitor 1 (Standard) is the analytical standard of LRRK2 inhibitor 1 (HY-111493). This product is intended for research and analytical applications. LRRK2 inhibitor 1 is a potent, selective and oral LRRK2 inhibitor with an pIC50 of 6.8.
Cat. No.: HY-171801
CAS No.: 3031514-69-6
Research Areas:
PROTAC LRRK2 Degrader-1 (compound 18) is a leucine-rich repeat kinase 2 (LRRK2) PROTAC degrader with an IC 50 value less than 10 nM. PROTAC LRRK2 Degrader-1 can be used in the research of Parkinson's disease .
Cat. No.: HY-151441
CAS No.: 2892451-45-3
Target:
Research Areas:
LRRK2-IN-5 (compound 25) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 1.2 and 16 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-5 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-5 can cross the blood-brain barrier .
Cat. No.: HY-151444
CAS No.: 2892451-17-9
Target:
Research Areas:
LRRK2-IN-6 (compound 22) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 4.6 and 49 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-6 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-6 can cross the blood-brain barrier .
Cat. No.: HY-15800
CAS No.: 1330003-04-7
Research Areas:
CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases [2] .
Cat. No.: HY-169576
CAS No.: 852375-30-5
Target:
Research Areas:
LRRK2-IN-16 (compound 25) is a LRRK2 kinase inhibitor with an IC50 < 5 μM. LRRK2-IN-16 can be utilized in neurodegenerative disorders and autoimmune disorders research .
Cat. No.: HY-172952
CAS No.: 2101821-86-5
Research Areas:
LRRK2-IN-17 (Compound 6) is an orally active LRRK2 inhibitor (IC50: 3.5 and 3.3 nM for WT and G2019S, respectively). LRRK2-IN-17 inhibits RET kinase (IC50: 59 nM). LRRK2-IN-17 can be used in cancer and Parkinson's disease (PD) research .
Cat. No.: HY-168041
Research Areas:
LRRK2-IN-15 is an LRRK2 inhibitor. The IC50 value for PBMC cells is 5 nM, and the IC50 value for BCRP is 1.5 μM. LRRK2-IN-15 can be used for research on Parkinson's disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
